Skip to content

Mechanical Ventilation- Weaning and Thoracic Impedance Tomography

Comparison Between Automated Pressure Support Ventilation, Variable Pressure Support Ventilation and Non-variable Pressure Support Ventilation in Weaning From Mechanical Ventilation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03018483
Enrollment
342
Registered
2017-01-12
Start date
2017-05-01
Completion date
2019-12-01
Last updated
2019-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weaning From Mechanical Ventilation

Brief summary

The aim of this multicenter, randomized controlled trial is to evaluate the weaning time from mechanical ventilation comparing non-variable PSV, variable PSV, and Smart CareTM. This study is a multicenter randomized controlled open trial comparing variable, non-variable pressure support ventilation and Smart CareTM in patients receiving mechanical ventilation for more than 24 hours who are able to be weaned. The aim of the study is to determine the duration of weaning from mechanical ventilation for each one of the above mentioned weaning methods

Interventions

DEVICEVariable PSV

Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician.

DEVICEConventional PSV

Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.

DEVICEAutomated PSV

Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.

DEVICENAVA

NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age≥18 years * duration of controlled mechanical ventilation≥ 24 h * temperature≤ 39°C * hemoglobin≥ 6 g/dl * ratio of arterial partial pressure of oxygen to inspiratory oxygen fraction - PaO2/FiO2≥150mmHg with positive end-expiratory pressure (PEEP)≤ 16 cmH2O * ability of the patient to breathe spontaneously * informed consent

Exclusion criteria

* patient participated in another interventional trial within the last four weeks before enrollment * peripheral neurological disease associated with impairment of the respiratory pump * muscular disease associated with impairment of the respiratory pump * unstable thorax with paradoxical chest wall movement * planned surgery under general anesthesia within 72 hours * difficult airway or intubation * existing tracheotomy at ICU admission * expected survival\<72 hours * home mechanical ventilation or on chronic oxygen therapy * suspected or confirmed pregnancy

Design outcomes

Primary

MeasureTime frameDescription
weaning timewithin 6 hoursweaning time defined as the time from randomization to successful extubation.

Countries

Italy

Contacts

Primary ContactMaria Vargas
vargas.maria82@gmail.com+39 3396876440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026